Videos

Anne Hubbard, MBA, Director of Health Policy, American Society for Radiation Oncology, discusses the Radiation Oncology Model, which may pave a path for use of an episode-based payment concept in the broader realm of cancer care.

Lee Fleisher, MD, discusses balancing the need for uniform quality care for all patients with finding the proper pathways for individual patients.

Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.

Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...

Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.

Elliot Fishman, MD, discusses imagining guidelines and the optimization of health care within oncology.

Matthew Lunning, DO, FACP, discusses the expansion of telehealth during the “COVID era,” highlighting the importance of face-to-face encounters between patients and health care providers, and suggesting ways to successfully meet this demand...

Ira Klein, MD, discusses design in clinical trials, touching on current issues such as clinical workflow and operational processes, and the barriers to participating in a clinical trial in community oncology.

In an interview exploring the progression-free survival and overall survival among patients with HER2-low metastatic breast cancer who received one or two previous lines of chemotherapy, Naoto Ueno, MD, highlights the impacts that trastuzumab...

Daniel Vaena, MD, West Cancer Center and Research Institute, summarizes his 2022 Oncology Clinical Pathways Congress presentation that covers the evolution and unmet needs of the pathways in metastatic urothelial cancer and the disparities in...